Pfizer’s Lyrica Will Undergo Phase IV Vision, Nerve Impairment Studies
This article was originally published in The Pink Sheet Daily
Executive Summary
Pfizer also commits to a post-marketing study of pregabalin’s propensity to induce CYP-enzyme metabolism. Lyrica is undergoing controlled substance scheduling by DEA. The European Medicines Agency says that study data suggest pregabalin is not a “prototypic” risk for abuse when compared to diazepam.